JY
SPRY icon

Jeff Yass’s ARS Pharmaceuticals SPRY Stock Holding History

Jeff Yass’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$923K Sell
115,200
-29,100
-20% -$250K ﹤0.01% 8397
2026
Q1 		$1.16M Buy
144,300
+32,600
+29% +$312K ﹤0.01% 7492
2025
Q4 		$1.3M Sell
111,700
-173,700
-61% -$1.69M ﹤0.01% 6581
2025
Q3 		$2.87M Buy
285,400
+160,700
+129% +$2.31M ﹤0.01% 5066
2025
Q2 		$2.18M Buy
124,700
+93,000
+293% +$1.34M ﹤0.01% 5616
2025
Q1 		$399K Sell
31,700
-22,900
-42% -$276K ﹤0.01% 9404
2024
Q4 		$576K Sell
54,600
-129,500
-70% -$1.81M ﹤0.01% 8320
2024
Q3 		$2.67M Sell
184,100
-821,300
-82% -$9.77M ﹤0.01% 4757
2024
Q2 		$8.56M Buy
1,005,400
+779,800
+346% +$6.92M ﹤0.01% 2688
2024
Q1 		$2.31M Buy
225,600
+193,300
+598% +$1.44M ﹤0.01% 5014
2023
Q4 		$177K Sell
32,300
-81,000
-71% -$355K ﹤0.01% 10806
2023
Q3 		$428K Buy
+113,300
New +$744K ﹤0.01% 8586
2023
Q2 		– Sell
-208,200
Closed -$1.36M – 13075
2023
Q1 		$1.36M Buy
208,200
+13,400
+7% +$103K ﹤0.01% 6051
2022
Q4 		$1.66M Buy
194,800
+30,500
+19% +$198K ﹤0.01% 5063
2022
Q3 		$868K Buy
164,300
+38,600
+31% +$190K ﹤0.01% 7000
2022
Q2 		$533K Buy
125,700
+84,300
+204% +$294K ﹤0.01% 8108
2022
Q1 		$145K Sell
41,400
-19,600
-32% -$85.3K ﹤0.01% 11590
2021
Q4 		$406K Buy
+61,000
New +$496K ﹤0.01% 9730

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jeff Yass's SPRY Position: Q2 2026 in Review

Jeff Yass reduced its ARS Pharmaceuticals (SPRY) stake by 3.5% in Q2 2026, selling an estimated $18.3K and leaving 58,413 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #10072.

Jeff Yass first reported a position in SPRY in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.48M in Q2 2025. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Jeff Yass held 58,413 shares of ARS Pharmaceuticals worth $468K as of Q2 2026.
  • Jeff Yass sold 2,124 ARS Pharmaceuticals shares in Q2 2026, an estimated $18.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10072 holding.
  • Jeff Yass first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • Jeff Yass's ARS Pharmaceuticals position peaked at $4.48M in Q2 2025.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.